Mavoglurant
Phase 1Small molecule
Mavoglurant is one of 23 small molecule programs targeting Alcohol Drinking. It is currently in Phase 1.
1
Indications
4
Total Trials
2
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
23 competitors in Alcohol Drinking
#DrugCompanyPhaseTrials
1Nicorette
PfizerApproved
Marinol
Alnylam PharmaceuticalsApproved
Namenda
AbbVieApproved
Inderal
WWyeth-Lederle Vaccines
Approved
Neurontin
VViatris Specialty LLC
Approved
Intuniv
PPromius Pharma, LLC
Approved
Chantix
PPrism Pharmaceuticals
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Topamax
WWim Janssens
Approved
Abilify
OtsukaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Neuroimaging1 trial
MRI1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Mavoglurant. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- YYale University